Cargando…

Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis

Liver fibrosis is a common feature of chronic liver disease. Activated hepatic stellate cells (HSCs) are the main drivers of extracellular matrix accumulation in liver fibrosis. Hence, a strategy for regulating HSC activation is crucial in treating liver fibrosis. Mesenchymal stem cells (MSCs) are m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chanbin, Kim, Minju, Han, Jinsol, Yoon, Myunghee, Jung, Youngmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615475/
https://www.ncbi.nlm.nih.gov/pubmed/34829827
http://dx.doi.org/10.3390/biomedicines9111598
_version_ 1784604113743380480
author Lee, Chanbin
Kim, Minju
Han, Jinsol
Yoon, Myunghee
Jung, Youngmi
author_facet Lee, Chanbin
Kim, Minju
Han, Jinsol
Yoon, Myunghee
Jung, Youngmi
author_sort Lee, Chanbin
collection PubMed
description Liver fibrosis is a common feature of chronic liver disease. Activated hepatic stellate cells (HSCs) are the main drivers of extracellular matrix accumulation in liver fibrosis. Hence, a strategy for regulating HSC activation is crucial in treating liver fibrosis. Mesenchymal stem cells (MSCs) are multipotent stem cells derived from various post-natal organs. Therapeutic approaches involving MSCs have been studied extensively in various diseases, including liver disease. MSCs modulate hepatic inflammation and fibrosis and/or differentiate into hepatocytes by interacting directly with immune cells, HSCs, and hepatocytes and secreting modulators, thereby contributing to reduced liver fibrosis. Cell-free therapy including MSC-released secretomes and extracellular vesicles has elicited extensive attention because they could overcome MSC transplantation limitations. Herein, we provide basic information on hepatic fibrogenesis and the therapeutic potential of MSCs. We also review findings presenting the effects of MSC itself and MSC-based cell-free treatments in liver fibrosis, focusing on HSC activation. Growing evidence supports the anti-fibrotic function of either MSC itself or MSC modulators, although the mechanism underpinning their effects on liver fibrosis has not been established. Further studies are required to investigate the detailed mechanism explaining their functions to expand MSC therapies using the cell itself and cell-free treatments for liver fibrosis.
format Online
Article
Text
id pubmed-8615475
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86154752021-11-26 Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis Lee, Chanbin Kim, Minju Han, Jinsol Yoon, Myunghee Jung, Youngmi Biomedicines Review Liver fibrosis is a common feature of chronic liver disease. Activated hepatic stellate cells (HSCs) are the main drivers of extracellular matrix accumulation in liver fibrosis. Hence, a strategy for regulating HSC activation is crucial in treating liver fibrosis. Mesenchymal stem cells (MSCs) are multipotent stem cells derived from various post-natal organs. Therapeutic approaches involving MSCs have been studied extensively in various diseases, including liver disease. MSCs modulate hepatic inflammation and fibrosis and/or differentiate into hepatocytes by interacting directly with immune cells, HSCs, and hepatocytes and secreting modulators, thereby contributing to reduced liver fibrosis. Cell-free therapy including MSC-released secretomes and extracellular vesicles has elicited extensive attention because they could overcome MSC transplantation limitations. Herein, we provide basic information on hepatic fibrogenesis and the therapeutic potential of MSCs. We also review findings presenting the effects of MSC itself and MSC-based cell-free treatments in liver fibrosis, focusing on HSC activation. Growing evidence supports the anti-fibrotic function of either MSC itself or MSC modulators, although the mechanism underpinning their effects on liver fibrosis has not been established. Further studies are required to investigate the detailed mechanism explaining their functions to expand MSC therapies using the cell itself and cell-free treatments for liver fibrosis. MDPI 2021-11-02 /pmc/articles/PMC8615475/ /pubmed/34829827 http://dx.doi.org/10.3390/biomedicines9111598 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lee, Chanbin
Kim, Minju
Han, Jinsol
Yoon, Myunghee
Jung, Youngmi
Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis
title Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis
title_full Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis
title_fullStr Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis
title_full_unstemmed Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis
title_short Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis
title_sort mesenchymal stem cells influence activation of hepatic stellate cells, and constitute a promising therapy for liver fibrosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615475/
https://www.ncbi.nlm.nih.gov/pubmed/34829827
http://dx.doi.org/10.3390/biomedicines9111598
work_keys_str_mv AT leechanbin mesenchymalstemcellsinfluenceactivationofhepaticstellatecellsandconstituteapromisingtherapyforliverfibrosis
AT kimminju mesenchymalstemcellsinfluenceactivationofhepaticstellatecellsandconstituteapromisingtherapyforliverfibrosis
AT hanjinsol mesenchymalstemcellsinfluenceactivationofhepaticstellatecellsandconstituteapromisingtherapyforliverfibrosis
AT yoonmyunghee mesenchymalstemcellsinfluenceactivationofhepaticstellatecellsandconstituteapromisingtherapyforliverfibrosis
AT jungyoungmi mesenchymalstemcellsinfluenceactivationofhepaticstellatecellsandconstituteapromisingtherapyforliverfibrosis